<DOC>
	<DOCNO>NCT00615784</DOCNO>
	<brief_summary>The purpose study evaluate activity bexarotene , retinoic acid class drug , patient Acute Myeloid Leukemia ( AML ) return resistant standard chemotherapy otherwise eligible conventional chemotherapy . Retinoic acids class drug relate Vitamin A , wide range effect within normal malignant cell affect cell growth cell death .</brief_summary>
	<brief_title>Phase II Study Bexarotene Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Age &gt; = 18 year Confirmed diagnosis AML proven bone marrow biopsy Must receive prior induction therapy conventional chemotherapy and/or Mylotarg otherwise eligible conventional chemotherapy ECOG performance status 02 Recovered toxicity prior chemotherapy History pancreatitis Active alcohol abuse Taken bexarotene past WBC &gt; 10,000/uL time enrollment Cytotoxic therapy within past 14 day hydrea , low dose cytarabine low dose Mylotarg Significant organ disfunction : total bilirubin &gt; 3x ULN , AST ALT &gt; 3 x ULN , creatinine &gt; 3 mg/dL , blood pressure support medication mechanical ventilation Active participant investigational treatment study AML Life expectancy le 1 month Use blood growth factor ( GCSF , GMCSF , Aranesp , erythropoietin , Neumega ) within 1 week prior treatment initiation Uncontrolled hyperlipidemia Known history HIV Known active CNS involvement AML Women childbearing potential active breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Bexarotene</keyword>
</DOC>